Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun 21;5(6):e11231.
doi: 10.1371/journal.pone.0011231.

The potential involvement of E-cadherin and beta-catenins in meningioma

Keiyu Zhou  1 , Guangtao Wang, Yirong Wang, Hanghuang Jin, Shuxu Yang, Chibo Liu
Affiliations

The potential involvement of E-cadherin and beta-catenins in meningioma

Keiyu Zhou et al. PLoS One. .

Abstract

Objective: To investigate the potential involvements of E-cadherin and beta-catenin in meningioma.

Methods: Immunohistochemistry staining was performed on samples from patients with meningioma. The results were graded according to the positive ratio and intensity of tissue immunoreactivity. The expression of E-cadherin and beta-catenin in meningioma was analyzed by its relationship with WHO2007 grading, invasion, peritumoral edema and postoperative recurrence.

Results: The positive rates of E-cadherin in meningioma WHO I, II, III were 92.69%, 33.33% and 0, respectively, (P<0.05); while the positive rates of beta-catenin in meningioma WHO I, II, III were 82.93%, 33.33% and 20.00%, respectively, (P<0.05). The positive rate of E-cadherin in meningioma without invasion (94.12%) was higher than that with invasion (46.67%) (P<0.05). The difference in the positive rate of beta-catenin between meningioma without invasion (88.24%) and meningioma with invasion (33.33%, P<0.05) was also statically significant. The positive rates of E-cadherin in meningioma with peritumoral edema 0, 1, 2, 3 were 93.75%, 85.71%, 60.00% and 0 respectively, (P<0.05); the positive rates of beta-catenin in meningioma with peritumoral edema 0, 1, 2, 3 were 87.50%, 85.71%, 30.00% and 0 respectively, (P<0.01). The positive rates of E- cadherin in meningioma with postoperative recurrence were 33.33%, and the positive rate with postoperative non-recurrence was 90.00% (P<0.01). The positive rates of beta-catenin in meningioma with postoperative recurrence and non-recurrence were 11.11%, 85.00%, respectively (P<0.01).

Conclusion: The expression levels of E- cadherin and beta-catenin correlated closely to the WHO 2007 grading criteria for meningioma. In atypical or malignant meningioma, the expression levels of E-cadherin and beta-catenin were significantly lower. The expression levels of E- cadherin and beta-catenin were also closely correlated with the invasion status of meningioma, the size of the peritumoral edema and the recurrent probabilities of the meningioma, all in an inverse correlationship. Taken together, the present study provided novel molecular targets in clinical treatments to meningioma.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. E-cadherin immunostaining on tissue of epithelial type of meningioma (WHO I grade), with amplification of 200X.
Expression level was determined as +.
Figure 2
Figure 2. β-catenin immunostaining on tissue of epithelia type of meningioma (WHO I grade), with amplification of 200X.
Expression level was determined as +.
Figure 3
Figure 3. E-cadherin immunostaining on tissue of fibrillar 1 type of meningioma (WHO I grade), with amplification of 200X.
Expression level was determined as ++.
Figure 4
Figure 4. β-catenin immunostaining on tissue of fibrillar 1 type of meningioma (WHO I grade), with amplification of 200X.
Expression level was determined as ++.
Figure 5
Figure 5. E-cadherin immunostaining on tissue of epithelial type of meningioma (WHO I grade), with amplification of 200X.
Expression level was determined as +++.
Figure 6
Figure 6. β-catenin immunostaining on tissue of malignant type of meningioma (WHO III grade), with amplification of 200X.
Expression level was determined as +.
See this image and copyright information in PMC

References

    1. Klaeboe L, Lonn S, Scheie D, Auvinen A, Christensen HC, et al. Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968–1997. Int J Cancer. 2005;117:996–1001. - PubMed
    1. Marosi C, Hassler M, Roessler K, Reni M, Sant M, et al. Meningioma. Crit Rev Oncol Hematol. 2008;67:153–171. - PubMed
    1. Jagannathan J, Oskouian RJ, Yeoh HK, Saulle D, Dumont AS. Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature. Skull Base. 2008;18:173–187. - PMC - PubMed
    1. Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, et al. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol. 2008;27:334–345. - PubMed
    1. Akat K, Bleck CK, Lee YM, Haselmann-Weiss U, Kartenbeck J. Characterization of a novel type of adherens junction in meningiomas and the derived cell line HBL-52. Cell Tissue Res. 2008;331:401–412. - PubMed

Publication types